5 Stock To Watch: BIIB, ACAD, APPL, CMG, MU
Michael Kramer | Mar 21, 2019 08:46AM ET
- S&P 500 Futures -5.50
- 10-Year Yield 2.52%
- Oil $59.93
- Dollar Index 96.21
- VIX 14.16
- Japan Nikkei +0.20%
- China Shanghai +0.35%
- Hong Kong HSI -0.85%
- South Korea Kospi +0.36%
- Australia ASX +0.03%
- German DAX -0.23%
- UK FTSE +0.62%
- Copper +1.23%
- Silver +1.61%
- Platinum +1.3%
I read a couple of comments today about how some seem to think the Fed knows something nobody else does. I would disagree because they were very slow to shift in this stance and it was about six-months that Chairman Powell was on a stage saying we are nowhere near neutral. I think this change in stance has more to do with structural issues caused by a low-interest rate environment around the world. The ECB’s move earlier this month to a more accommodative policy all but sealed the deal for the Fed.
h2 Commodities/h2 h2 Oil/h2It wasn’t just equities that the Fed unleashed with its new stance on monetary policy. Lower interest rates mean a weaker dollar and that is also bullish of commodities. Oil prices are rising and are approaching a potentially big break out should it rise above $61.70.
Copper is breaking out today and is rising back to $2.95, and is potentially on its way back to $3.01. We spoke about the potential for a break out in Copper earlier this week.
The S&P 500 is pointing to a lower open to start the day, but support for the index should be firm around the 2,810 to 2,815 level.
Get The News You Want
Biogen (NASDAQ:BIIB) shares are tanking today by 26% after the company said it was planning to stop its trials for aducanumab in Alzheimer’s Disease. A big disappointment for the company. Many investors had been very hopeful for this drug at one point about a year ago. That has changed. Now the stock is falling below critical levels of support at $245 and could be at risk of falling to $206.
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) shares are trading lower this morning, probably because of the Biogen news related to Alzheimer’s. But make no mistake, Acadia dementia psychosis study is in no way similar to Biogen. The uptrend is still very much in place.
Apple (NASDAQ:AAPL) received two upgrades on March 21. Needham upgraded the stock to a strong buy from buy and raised its price target to $225 from $180. Also, Citigroup (NYSE:C) increased its price target to $220 from $170. Apple continues to move towards resistance at $195, the next major inflection point.
Chipotle Mexican Grill Inc (NYSE:CMG)’s price target was raised today at Argus to $770 from $670. The stock is now sitting at resistance at $670. The stock may be on its way to $705.
Micron Technology Inc (NASDAQ:MU) was downgraded to sell from neutral at Citigroup Inc (NYSE:C), and the price target was lowered to $30. The stock is still butting up against resistance t $42.10, and I would be surprised if the stock continued to hold these gains once the market opens and all big institutions start to participate.
Ok, good luck!
Original post
/h2
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.